[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...
.

Osi-774 therapy in advanced squamous head and neck cancer

A phase two trial of OSI-774, a selective orally active EGFR (epidermal growth factor receptor) tyrosine kinase antagonist, in recurrent (after first therapy) squamous cell carcinoma of the head and neck region, was reported in a Canadian/Aamerican multi-institutional study reported at the influential American Society of Clinical Oncolgy meeting (San Francisco, May 2001). That there were some good responses encountered is very encouraging indeed as these parients have not previously proved readily responsive to orthodox therapies.